Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01544595
Registration number
NCT01544595
Ethics application status
Date submitted
28/02/2012
Date registered
6/03/2012
Date last updated
20/12/2018
Titles & IDs
Public title
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Query!
Scientific title
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Query!
Secondary ID [1]
0
0
2012-000533-39
Query!
Secondary ID [2]
0
0
CAIN457A2302E1
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Moderate to Severe Plaque-type Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Secukinumab (AIN457)
Treatment: Drugs - Placebo
Placebo Comparator: PASI 75 Responders - PASI 75 responders participated in "randomized withdrawal". Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen.
Experimental: Partial responders - Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
Treatment: Drugs: Secukinumab (AIN457)
Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions.
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68
Query!
Assessment method [1]
0
0
The primary variable was the cumulative rate of patients who lost PASI 75 response up to Week 68 (time=0 being defined as Week 52).
Loss of PASI 75 response was analyzed by means of a survival analysis defining "loss of PASI 75 response" as "failure". The term cumulative rate corresponded to 1 minus the survival function within this survival analysis, and the cumulative rate and the survival functions were dependent on time t.
PASI 75 response: patients achieving = 75% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 75 responders.
Query!
Timepoint [1]
0
0
At week 68 (16 weeks after week 52)
Query!
Secondary outcome [1]
0
0
Number of Participants With PASI 50, PASI 75, PASI 90, PASI 100 and IGA Mod 2011 0 or 1 (Observed Data) - Randomized Withdrawal Period
Query!
Assessment method [1]
0
0
Psoriasis Area and Severity Index (PASI) 75 responder at week 52. Patients in the placebo groups were not evaluable after re-treatment with Secukinumab.
PASI 75 Responders: patients with a PASI 75 response (patients achieving =75% improvement [reduction] in PASI score compared to baseline of the core study).
PASI 50 response: patients achieving = 50% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 50 responders.
PASI 90 response: patients achieving = 90% improvement (reduction) in PASI score compared to baseline of the core study were defined as PASI 90 responders.
PASI 100 response/remission: complete clearing of psoriasis (PASI=0)
Query!
Timepoint [1]
0
0
Week 52, 104, and 156
Query!
Secondary outcome [2]
0
0
Number of Participants With PASI 50, PASI 75, PASI 90, and PASI 100 (Observed Data) - Entire Study Period
Query!
Assessment method [2]
0
0
Psoriasis Area and Severity Index (PASI) scoring system: The average degree of severity of each sign in each of the four body regions was assigned a score of 0-4. The area covered by lesions on each body region was estimated as a percentage of the total area of that particular body region.
Query!
Timepoint [2]
0
0
Week 52, Week 104, Week 156, week 208, week 260
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline for PASI Score Over Time (Observed Data) - Randomized Withdrawal Period
Query!
Assessment method [3]
0
0
The improvement (decrease from baseline) in PASI total scores observed at Week 52.
Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.
Query!
Timepoint [3]
0
0
Week 52, 104, and 156
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline for PASI Score Over Time (Observed Data) - Entire Study Period
Query!
Assessment method [4]
0
0
Perc. change = 100 x Abs. change /Base. (Abs. change = Post - Base) For each post-baseline visit only patients with a value at both baseline and the respective post-baseline visit are included.
Query!
Timepoint [4]
0
0
Week 52, Week 104, Week 156, week 208, week 260
Query!
Secondary outcome [5]
0
0
Number of Participants in Each IGA Mod 2011 Category (Observed Data)- Randomized Withdrawal Period
Query!
Assessment method [5]
0
0
Investigator Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0: Clear (No signs of psoriasis. Post-inflammatory hyperpigmentation could be Present). Score 1: Almost clear (Normal to pink coloration of lesions; no thickening; no to minimal focal scaling), Score 2: Mild (Pink to light red coloration; just detectable to mild thickening; predominantly fine scaling). Score 3: Moderate (Dull bright red, clearly distinguishable erythema; clearly distinguishable to moderate thickening; moderate scaling). Score 4: Severe (Bright to deep dark red coloration; severe thickening with hard edges; severe /coarse scaling covering almost all or all lesions).
Patients in the placebo groups were not evaluable after re-treatment with Secukinumab
Query!
Timepoint [5]
0
0
Week 52 (baseline), 104, and 156
Query!
Secondary outcome [6]
0
0
Number of Participants in Each IGA Mod 2011 Category (Observed Data) - Entire Study Period
Query!
Assessment method [6]
0
0
Investigator's Global Assessment (IGA) mod 2011; scale from 0 - 4. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions)
Query!
Timepoint [6]
0
0
Week 52, Week 104, Week 156, week 208, week 260
Query!
Secondary outcome [7]
0
0
Number of Participants With IGA Mod 2011 0/1 Response (Observed Data) - Entire Study Period
Query!
Assessment method [7]
0
0
Investigator's Global Assessment (IGA) mod 2011 0/1. Score 0= clear (no signs of psoriasis) Score 1 = almost clear no to minimal local scaling) Score 2 = mild (predominantly fine scaling) Score 3 = moderate (moderate scaling) Score 4 = severe (severe/coarse scaling covering almost all or all lesions) Based on this scale, a patient was considered as IGA mod 2011 0/1 responder if the patient achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline.
Query!
Timepoint [7]
0
0
Week 52, Week 104, Week 156, week 208, week 260
Query!
Secondary outcome [8]
0
0
Percent of Participants With Loss of IGA Mod 2011 0 or 1 Response Over Time for Subjects With IGA Mod 2011 0 or 1 Response at Week 52 - Randomized Withdrawal Period
Query!
Assessment method [8]
0
0
Summary for loss of IGA mod 2011 0 or 1 response over time for patients with response at Week 52.
time = 0 refers to Week 52
Query!
Timepoint [8]
0
0
Week 68
Query!
Secondary outcome [9]
0
0
Percent of Participants With PASI 75 Response - Treatment Period for Re-treated After Relapse
Query!
Assessment method [9]
0
0
PASI 75 response since reinitiating treatment after relapse. time = 0 refers to Week 52
Query!
Timepoint [9]
0
0
up to week 260
Query!
Secondary outcome [10]
0
0
Percent of Participants With IGA Mod 0 or 1 Response - Treatment Period for Re-treated After Relapse
Query!
Assessment method [10]
0
0
IGA mod 2011 0 or 1 response since reinitiating treatment after relapse for subjects with IGA 0 or 1 response at week 52 and not have IGA 0 or 1 response at relapse.
time = 0 refers to Week 52
Query!
Timepoint [10]
0
0
up to week 260
Query!
Secondary outcome [11]
0
0
Percent pf Participants With Relapse Over Time - Randomized Withdrawal Period
Query!
Assessment method [11]
0
0
Time 0 = week 52
Query!
Timepoint [11]
0
0
up to week 156
Query!
Secondary outcome [12]
0
0
Percent of Participants With Relapse After Last Injection
Query!
Assessment method [12]
0
0
Relapse: when the achieved maximal PASI improvement from baseline of core study was reduced by >50%.
Time 0 = week 52
Query!
Timepoint [12]
0
0
up to week 16
Query!
Secondary outcome [13]
0
0
Percent of Participants With Rebound After Last Injection
Query!
Assessment method [13]
0
0
Rebound: PASI increases to > 125% of baseline (where baseline is the PASI at the randomization of the core study) or presence of new pustular psoriasis, new erythrodermic psoriasis or more inflammatory psoriasis occurring within 8 Weeks of stopping therapy (after the last dose of study treatment received). Rebound like event (RLE) was defined as increase of PASI of > 125% from baseline value or occurrence of new pustular, new erythrodermic or more inflammatory psoriasis any time after stopping therapy (last treatment administered) up to Week 68. Rebound was evaluated for the patients randomized to the placebo groups in the extension study; hence these patients received the last dose of secukinumab during the core studies.
Query!
Timepoint [13]
0
0
up to week 68
Query!
Secondary outcome [14]
0
0
Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Randomized Withdrawal Period (Observed Data)
Query!
Assessment method [14]
0
0
Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.
Query!
Timepoint [14]
0
0
Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156
Query!
Secondary outcome [15]
0
0
Number of Participants With Dermatology Life Quality Index Response (DLQI 0 or 1) - Entire Treatment Period
Query!
Assessment method [15]
0
0
Dermatology Life Quality Index (DLQI) scores range from 0 to 30. Lower absolute scores on DLQI indicate better/improved health-related quality-of life impairment.
Query!
Timepoint [15]
0
0
Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156
Query!
Secondary outcome [16]
0
0
EQ-5D Health State Assessment (Observed Value) - Randomized Withdrawal Period
Query!
Assessment method [16]
0
0
EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Query!
Timepoint [16]
0
0
Week 52 (baseline), 64, 76, 88, 104, 116, 128, 140, and 156
Query!
Secondary outcome [17]
0
0
EQ-5D Health State Assessment (Observed Value) - Entire Study Period
Query!
Assessment method [17]
0
0
EQ-5D: EuroQOL 5-Dimension Health Status Questionnaire. The EQ-5D© is a generic instrument to assess each patient's health status. It provides a simple descriptive profile and a single index value for health status. The EQ visual analog scale records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Query!
Timepoint [17]
0
0
week 64, 76, 88, 104, 116, 128, 140, and 156
Query!
Secondary outcome [18]
0
0
Clinical Laboratory Evaluation - Hematology Parameters: Incidence Rate for Participants With Clinically CTCAE - Randomized Withdrawal Period
Query!
Assessment method [18]
0
0
CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.
IR=incidence rate per 100 subject years
Query!
Timepoint [18]
0
0
Week 52-156
Query!
Secondary outcome [19]
0
0
Clinical Laboratory Evaluation: Number of Participants With Clinically CTCAE - Entire Study Period
Query!
Assessment method [19]
0
0
CTCAE: common terminology criteria for adverse events. A subject with multiple variable measurements is counted only once under the worst condition. LLN = lower limit of normal.
Query!
Timepoint [19]
0
0
approximately 4 years
Query!
Secondary outcome [20]
0
0
Electrocardiogram: Incidence of Participants With ECG Test Results - Randomized Withdrawal Period
Query!
Assessment method [20]
0
0
QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.
IR=incidence rate per 100 subject years.
Query!
Timepoint [20]
0
0
Week 52 - 156
Query!
Secondary outcome [21]
0
0
Electrocardiogram: Number of Participants With ECG Test Results - Entire Treatment Period
Query!
Assessment method [21]
0
0
QTcB: QT interval corrected using Bazett's formula QTcF: QT interval corrected using Fridericia's formula A patient with multiple variable measurements is counted only once under the worst condition.
Query!
Timepoint [21]
0
0
Approximately 4 years
Query!
Eligibility
Key inclusion criteria
Key
Completed the full study treatment period of 52 weeks in preceding phase III studies, and
have been receiving secukinumab treatment during the maintenance phase of the preceding
phase III studies, and show at least a partial response (PASI 50 or better) at Week 52 of
the preceding phase III studies.
Written informed consent form.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
A protocol deviation in either of the preceding phase III studies which according to the
investigator prevented the meaningful analysis of the extension study for the individual
subject.
Ongoing use of prohibited psoriasis or non-psoriasis treatments.
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female
after conception and until the termination of gestation, confirmed by a positive hCG
laboratory test (>10 mIU/mL).
Women of child-bearing potential, defined as all women physiologically capable of becoming
pregnant, unwilling to use effective contraception during the study and for 16 weeks after
stopping treatment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
19/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/06/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1147
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Carlton
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [4]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oregon
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Rhode Island
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Utah
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Mendoza
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Bruxelles
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Gent
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Liege
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
New Brunswick
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Nova Scotia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Ontario
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Quebec
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Atlantico
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Barranquilla
Query!
Country [35]
0
0
Colombia
Query!
State/province [35]
0
0
Bogota
Query!
Country [36]
0
0
Estonia
Query!
State/province [36]
0
0
Tallinn
Query!
Country [37]
0
0
Estonia
Query!
State/province [37]
0
0
Tartu
Query!
Country [38]
0
0
Finland
Query!
State/province [38]
0
0
Helsinki
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Cedex 10
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux Cedex
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Marseille Cedex 9
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Martigues
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Nice Cedex 3
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Reims
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Toulouse Cedex
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Nordrhein-Westfalen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Augsburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bielefeld
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Bochum
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Bonn
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Darmstadt
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Erfurt
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Erlangen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Essen
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Frankfurt
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Gera
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Goettingen
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Greifswald
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Hamburg
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Hanau
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Heidelberg
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Kiel
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Krefeld
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Muenchen
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Muenster
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Osnabrueck
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Plauen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Recklinghausen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Schwerin
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Tuebingen
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Wuppertal
Query!
Country [74]
0
0
Guatemala
Query!
State/province [74]
0
0
Guatemala City
Query!
Country [75]
0
0
Hungary
Query!
State/province [75]
0
0
Budapest
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Debrecen
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Kaposvar
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Miskolc
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Szeged
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Szombathely
Query!
Country [81]
0
0
Iceland
Query!
State/province [81]
0
0
Kopavogur
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Afula
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Petach Tikva
Query!
Country [84]
0
0
Israel
Query!
State/province [84]
0
0
Ramat Gan
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
CT
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
MO
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Aichi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Fukuoka
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Gunma
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Hokkaido
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Hyogo
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Ibaraki
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Kanagawa
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Kyoto
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Tokyo
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Korea
Query!
Country [97]
0
0
Korea, Republic of
Query!
State/province [97]
0
0
Seocho-gu
Query!
Country [98]
0
0
Korea, Republic of
Query!
State/province [98]
0
0
Busan
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Gwangju
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Seoul
Query!
Country [101]
0
0
Latvia
Query!
State/province [101]
0
0
LVA
Query!
Country [102]
0
0
Latvia
Query!
State/province [102]
0
0
Riga
Query!
Country [103]
0
0
Lithuania
Query!
State/province [103]
0
0
LTU
Query!
Country [104]
0
0
Lithuania
Query!
State/province [104]
0
0
Vilnius
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Lodz
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Poznan
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Wroclaw
Query!
Country [108]
0
0
Romania
Query!
State/province [108]
0
0
Bucuresti
Query!
Country [109]
0
0
Singapore
Query!
State/province [109]
0
0
Singapore
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Barcelona
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Cataluña
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Comunidad Valenciana
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Madrid
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Malmo
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Uppsala
Query!
Country [116]
0
0
Taiwan
Query!
State/province [116]
0
0
Hsin Chu
Query!
Country [117]
0
0
Taiwan
Query!
State/province [117]
0
0
Taichung
Query!
Country [118]
0
0
Taiwan
Query!
State/province [118]
0
0
Taipei
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Devon
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
England
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Manchester
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Somerset
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
West Midlands
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Harrogate
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Nuneaton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was an extension study of secukinumab prefilled syringes in subjects with moderate to
severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with
secukinumab. Subjects on secukinumab at the end of treatment period in phase III studies
(e.g., ongoing CAIN457A2302 and CAIN457A2303 and potentially other secukinumab phase III
studies) were eligible to join this extension study. This extension study was planned to
collect an additional 2 years of long-term efficacy, safety, and tolerability data of
secukinumab in either continuous or interrupted therapy (randomized withdrawal period) in
subjects showing at least partial response to secukinumab and completing treatment period on
secukinumab in previous phase III studies. In this extension study, the prefilled syringe
(PFS) liquid formulation of secukinumab were used.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01544595
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01544595
Download to PDF